Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Markus Hoffmann

Showing results (201-210 of 312) with videos related to

Pageof 32
Sort By:
Iscience|May 30, 2024
Rapid spread of the SARS-CoV-2 JN.1 lineage is associated with increased neutralization evasionLu Zhang, Alexandra Dopfer-Jablonka, Anne Cossmann, et al.
The Lancet. Microbe|June 6, 2025
Host cell entry and neutralisation sensitivity of SARS-CoV-2 BA.3.2Lu Zhang, Amy Kempf, Inga Nehlmeier, et al.
Plos One|September 12, 2013
Differential sensitivity of bat cells to infection by enveloped RNA viruses: coronaviruses, paramyxoviruses, filoviruses, and influenza virusesMarkus Hoffmann, Marcel Alexander Müller, Jan Felix Drexler, et al.
Plos Pathogens|April 22, 2021
The SARS-CoV-2 and other human coronavirus spike proteins are fine-tuned towards temperature and proteases of the human airwaysManon Laporte, Valerie Raeymaekers, Ria Van Berwaer, et al.
Communications Biology|July 8, 2022
Peptidomimetic inhibitors of TMPRSS2 block SARS-CoV-2 infection in cell cultureLukas Wettstein, Philip Maximilian Knaff, Christian Kersten, et al.
Cell|March 7, 2020
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease InhibitorMarkus Hoffmann, Hannah Kleine-Weber, Simon Schroeder, et al.
Mbio|April 25, 2022
Evidence for an ACE2-Independent Entry Pathway That Can Protect from Neutralization by an Antibody Used for COVID-19 TherapyMarkus Hoffmann, Anzhalika Sidarovich, Prerna Arora, et al.
Cell Reports|October 11, 2018
Entry, Replication, Immune Evasion, and Neurotoxicity of Synthetically Engineered Bat-Borne Mumps VirusNadine Krüger, Christian Sauder, Sarah Hüttl, et al.
European Journal of Immunology|March 7, 2022
Augmented neutralization of SARS-CoV-2 Omicron variant by boost vaccination and monoclonal antibodiesSebastian R Schulz, Markus Hoffmann, Edith Roth, et al.
Neurotrauma Reports|January 12, 2022
Evaluation of Acute Glial Fibrillary Acidic Protein and Ubiquitin C-Terminal Hydrolase-L1 Plasma Levels in Traumatic Brain Injury Patients with and without Intracranial LesionsPeter Biberthaler, Ksenia Musaelyan, Sandro Krieg, et al.
Pageof 32

Showing results (201-210 of 312) with videos related to

Sort By:
Pageof 32
Iscience|May 30, 2024
Rapid spread of the SARS-CoV-2 JN.1 lineage is associated with increased neutralization evasionLu Zhang, Alexandra Dopfer-Jablonka, Anne Cossmann, et al.
The Lancet. Microbe|June 6, 2025
Host cell entry and neutralisation sensitivity of SARS-CoV-2 BA.3.2Lu Zhang, Amy Kempf, Inga Nehlmeier, et al.
Plos One|September 12, 2013
Differential sensitivity of bat cells to infection by enveloped RNA viruses: coronaviruses, paramyxoviruses, filoviruses, and influenza virusesMarkus Hoffmann, Marcel Alexander Müller, Jan Felix Drexler, et al.
Plos Pathogens|April 22, 2021
The SARS-CoV-2 and other human coronavirus spike proteins are fine-tuned towards temperature and proteases of the human airwaysManon Laporte, Valerie Raeymaekers, Ria Van Berwaer, et al.
Communications Biology|July 8, 2022
Peptidomimetic inhibitors of TMPRSS2 block SARS-CoV-2 infection in cell cultureLukas Wettstein, Philip Maximilian Knaff, Christian Kersten, et al.
Cell|March 7, 2020
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease InhibitorMarkus Hoffmann, Hannah Kleine-Weber, Simon Schroeder, et al.
Mbio|April 25, 2022
Evidence for an ACE2-Independent Entry Pathway That Can Protect from Neutralization by an Antibody Used for COVID-19 TherapyMarkus Hoffmann, Anzhalika Sidarovich, Prerna Arora, et al.
Cell Reports|October 11, 2018
Entry, Replication, Immune Evasion, and Neurotoxicity of Synthetically Engineered Bat-Borne Mumps VirusNadine Krüger, Christian Sauder, Sarah Hüttl, et al.
European Journal of Immunology|March 7, 2022
Augmented neutralization of SARS-CoV-2 Omicron variant by boost vaccination and monoclonal antibodiesSebastian R Schulz, Markus Hoffmann, Edith Roth, et al.
Neurotrauma Reports|January 12, 2022
Evaluation of Acute Glial Fibrillary Acidic Protein and Ubiquitin C-Terminal Hydrolase-L1 Plasma Levels in Traumatic Brain Injury Patients with and without Intracranial LesionsPeter Biberthaler, Ksenia Musaelyan, Sandro Krieg, et al.
Pageof 32